Loading...
Market
KT-621 Phase 1 Preliminary Efficacy by Mid-2025
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Kymera Therapeutics' official press releases or clinical trial registries
Story
Kymera ($KYMR) Reports Milestone in Phase 1 Trial for KT-621 STAT6 Degrader
Oct 25, 2024, 01:04 PM
Kymera Therapeutics has announced the dosing of the first participant in a Phase 1 clinical trial for KT-621, a first-in-class oral STAT6 degrader. KT-621 targets STAT6, a historically undrugged transcription factor in the IL-4/IL-13 signaling pathways, which is a central driver of T helper type 2 (TH2) inflammation in allergic diseases. The trial represents a significant milestone in the treatment of TH2 immuno-inflammatory diseases. KT-621 is designed to be taken once daily.
View original story
Similar markets
Trial halted • 25%
Limited efficacy • 25%
Moderate efficacy • 25%
High efficacy • 25%
Positive efficacy and safety • 25%
Positive efficacy, negative safety • 25%
Negative efficacy • 25%
Inconclusive • 25%
Exceeds expectations • 25%
Meets expectations • 25%
Below expectations • 25%
Study discontinued • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Highly Effective • 25%
Moderately Effective • 25%
Minimally Effective • 25%
Ineffective • 25%
Positive results with MRD-negative CR • 25%
Mixed results • 25%
Negative results • 25%
Trial discontinued • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial extended • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Trial halted • 25%